Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation

Paris Roach, Lilly Yue, Vipin Arora

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

OBJECTIVE - Humalog Mix25 is a manufactured premixed insulin formulation containing insulin lispro and a novel insulin lispro-protamine formulation (NPL) in a ratio of 25:75%. The objective of this study was to compare Humalog Mix25 to human insulin 30/70 (30% regular insulin/70% NPH) with respect to glycemic control. RESEARCH DESIGN AND METHODS - Humalog Mix25 was compared with human insulin 30/70 in 89 individuals with type 2 diabetes during a 6-month randomized open-label two-period crossover study. Each insulin was administered twice daily, before the morning and evening meals. Information regarding self-monitored blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG ≤3.0 mmol/l), insulin dose, and HbA(1c) was collected. RESULTS - Treatment with Humalog Mix25 resulted in better postprandial glycemic control after the morning and evening meals compared with treatment with human insulin 30/70. Overall glycemic control and the incidence of hypoglycemia were comparable between the treatments. CONCLUSIONS - In comparison to treatment with human insulin 30/70, twice daily administration of Humalog Mix25 resulted in improved postprandial glycemic control, similar overall glycemic control, and the convenience of dosing immediately before meals.

Original languageEnglish (US)
Pages (from-to)1258-1261
Number of pages4
JournalDiabetes Care
Volume22
Issue number8
DOIs
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

Insulin Lispro
Protamines
Insulin
Breakfast
Hypoglycemic Agents
Blood Glucose
insulin lispro, isophane insulin lispro drug combination (25:75)
Hypoglycemia
Cross-Over Studies
Type 2 Diabetes Mellitus
Signs and Symptoms
Meals
Research Design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. / Roach, Paris; Yue, Lilly; Arora, Vipin.

In: Diabetes Care, Vol. 22, No. 8, 08.1999, p. 1258-1261.

Research output: Contribution to journalArticle

@article{077d66ba658f4b64b7e76ab158116a15,
title = "Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation",
abstract = "OBJECTIVE - Humalog Mix25 is a manufactured premixed insulin formulation containing insulin lispro and a novel insulin lispro-protamine formulation (NPL) in a ratio of 25:75{\%}. The objective of this study was to compare Humalog Mix25 to human insulin 30/70 (30{\%} regular insulin/70{\%} NPH) with respect to glycemic control. RESEARCH DESIGN AND METHODS - Humalog Mix25 was compared with human insulin 30/70 in 89 individuals with type 2 diabetes during a 6-month randomized open-label two-period crossover study. Each insulin was administered twice daily, before the morning and evening meals. Information regarding self-monitored blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG ≤3.0 mmol/l), insulin dose, and HbA(1c) was collected. RESULTS - Treatment with Humalog Mix25 resulted in better postprandial glycemic control after the morning and evening meals compared with treatment with human insulin 30/70. Overall glycemic control and the incidence of hypoglycemia were comparable between the treatments. CONCLUSIONS - In comparison to treatment with human insulin 30/70, twice daily administration of Humalog Mix25 resulted in improved postprandial glycemic control, similar overall glycemic control, and the convenience of dosing immediately before meals.",
author = "Paris Roach and Lilly Yue and Vipin Arora",
year = "1999",
month = "8",
doi = "10.2337/diacare.22.8.1258",
language = "English (US)",
volume = "22",
pages = "1258--1261",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "8",

}

TY - JOUR

T1 - Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation

AU - Roach, Paris

AU - Yue, Lilly

AU - Arora, Vipin

PY - 1999/8

Y1 - 1999/8

N2 - OBJECTIVE - Humalog Mix25 is a manufactured premixed insulin formulation containing insulin lispro and a novel insulin lispro-protamine formulation (NPL) in a ratio of 25:75%. The objective of this study was to compare Humalog Mix25 to human insulin 30/70 (30% regular insulin/70% NPH) with respect to glycemic control. RESEARCH DESIGN AND METHODS - Humalog Mix25 was compared with human insulin 30/70 in 89 individuals with type 2 diabetes during a 6-month randomized open-label two-period crossover study. Each insulin was administered twice daily, before the morning and evening meals. Information regarding self-monitored blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG ≤3.0 mmol/l), insulin dose, and HbA(1c) was collected. RESULTS - Treatment with Humalog Mix25 resulted in better postprandial glycemic control after the morning and evening meals compared with treatment with human insulin 30/70. Overall glycemic control and the incidence of hypoglycemia were comparable between the treatments. CONCLUSIONS - In comparison to treatment with human insulin 30/70, twice daily administration of Humalog Mix25 resulted in improved postprandial glycemic control, similar overall glycemic control, and the convenience of dosing immediately before meals.

AB - OBJECTIVE - Humalog Mix25 is a manufactured premixed insulin formulation containing insulin lispro and a novel insulin lispro-protamine formulation (NPL) in a ratio of 25:75%. The objective of this study was to compare Humalog Mix25 to human insulin 30/70 (30% regular insulin/70% NPH) with respect to glycemic control. RESEARCH DESIGN AND METHODS - Humalog Mix25 was compared with human insulin 30/70 in 89 individuals with type 2 diabetes during a 6-month randomized open-label two-period crossover study. Each insulin was administered twice daily, before the morning and evening meals. Information regarding self-monitored blood glucose (BG), hypoglycemic episodes (hypoglycemic signs or symptoms or BG ≤3.0 mmol/l), insulin dose, and HbA(1c) was collected. RESULTS - Treatment with Humalog Mix25 resulted in better postprandial glycemic control after the morning and evening meals compared with treatment with human insulin 30/70. Overall glycemic control and the incidence of hypoglycemia were comparable between the treatments. CONCLUSIONS - In comparison to treatment with human insulin 30/70, twice daily administration of Humalog Mix25 resulted in improved postprandial glycemic control, similar overall glycemic control, and the convenience of dosing immediately before meals.

UR - http://www.scopus.com/inward/record.url?scp=0032787906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032787906&partnerID=8YFLogxK

U2 - 10.2337/diacare.22.8.1258

DO - 10.2337/diacare.22.8.1258

M3 - Article

C2 - 10480767

AN - SCOPUS:0032787906

VL - 22

SP - 1258

EP - 1261

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 8

ER -